Neurocrine Biosciences Reports Positive Top-line Data From Phase 3 Study Of Crinecerfont
(RTTNews) - Neurocrine Biosciences, Inc. (NBIX) announced Tuesday positive top-line data from the Phase 3 CAHtalyst Adult Study evaluating the efficacy, safety, and tolerability of crinecerfont in adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD).
The Phase 3 study met its primary endpoint at Week 24, demonstrating that treatment with crinecerfont resulted in a statistically significant percent reduction in daily glucocorticoid (GC) dose versus placebo while maintaining androgen control.
The study also met important key secondary endpoints, with a statistically significant decrease in androstenedione at Week 4 versus placebo. At Week 24, approximately 63% of patients on crinecerfont achieved a reduction to a physiologic GC dose versus approximately 18% on placebo.
Crinecerfont was generally well tolerated. The most common adverse events during the double-blind, placebo-controlled period of the trial were fatigue, headache, and coronavirus infection. There were few serious adverse events, with none assessed as related to crinecerfont.
Neurocrine Biosciences Reaches Settlement On INGREZZA ANDA Litigation
UK Labor Market Cools In Q2
U.S. Consumer Prices Increase 0.2% In July, In Line With Estimates
Cardinal Health Lifts FY26 Outlook, But Stock Down As Q4 Revenues Miss Street; To Buy Solaris Health
U.S. Consumer Prices Increase In Line With Estimates In July
German ZEW Economic Confidence Deteriorates On Trade Deal
Bay Street Likely To Open Flat Or Slightly Higher
